3,5-二苄氧基苯基环氧乙烷 | 50841-47-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 3,5-二苄氧基苯基环氧乙烷
• 中文别名: 2(1H)-异喹啉羧酸,1-[(4-叠氮-3-碘苯基)甲基]-6,7-二[(乙酯基&lt乙氧羰基&gt)氧代]-3,4-二氢-,9H-芴-9-基甲基酯
• 英文名称: 3,5-dibenzilossi-1-epossietilbenzene
• 英文别名: 2-[3,5-bis(benzyloxy)phenyl]oxirane；2-(3,5-dibenzyloxyphenyl)-oxirane；[3,5-Bis(phenylmethoxy)phenyl]oxirane；2-[3,5-bis(phenylmethoxy)phenyl]oxirane
• CAS: 50841-47-9
• 化学式: C₂₂H₂₀O₃
• 分子量: 332.399
• InChiKey: IXYYQIMVOHFSDN-UHFFFAOYSA-N

物化性质

• 熔点：
  40-44°C
• 溶解度：
  可溶于氯仿（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  25
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  31
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2910900090

反应信息

• 作为反应物：
  描述：

  3,5-二苄氧基苯基环氧乙烷 在 palladium on activated charcoal 硫酸 、 氨 、 氢气 作用下， 以 甲醇 、 正丁醇 为溶剂， 反应 82.0h， 生成 isobutyl 3-<2-(3,5-dihydroxyphenyl)-2-hydroxy-ethylamino>-butyrate, sulfate
  参考文献：
  名称：

  Albrecht; Loge, European Journal of Medicinal Chemistry, 1985, vol. 20, # 1, p. 51 - 55

  摘要：

  DOI：
• 作为产物：
  描述：

  1-[3,5-二(苯基甲氧基)苯基]-2-溴乙烷-1-酮 在 sodium tetrahydroborate 作用下， 以 甲醇 、 水 为溶剂， 反应 2.0h， 生成 3,5-二苄氧基苯基环氧乙烷
  参考文献：
  名称：

  Meglio, P. de; Carissimi, M.; Ravenna, F., Farmaco, Edizione Scientifica, 1980, vol. 35, # 3, p. 202 - 230

  摘要：

  DOI：

文献信息

• PREPARATION OF (R,R)-FENOTEROL AND (R,R)-OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE
  申请人：Wainer Irving W.

  公开号：US20100168245A1

  公开（公告）日：2010-07-01

  This disclosure concerns the discovery of (R,R)- and (R,S)-fenoterol analogues which are highly effective at binding β2-adrenergic receptors. Exemplary chemical structures for these analogues are provided. Also provided are pharmaceutical compositions including the disclosed (R,R)-fenoterol and fenoterol analogues, and methods of using such compounds and compositions for the treatment of cardiac disorders such as congestive heart failure and pulmonary disorders such as asthma or chronic obstructive pulmonary disease.

  本公开涉及发现(R,R)-和(R,S)-芬特罗类似物，它们在结合β2-肾上腺素能受体方面具有高度有效性。提供了这些类似物的示例化学结构。还提供了包括披露的(R,R)-芬特罗和芬特罗类似物的制药组合物，以及使用这些化合物和组合物治疗心脏疾病（如充血性心力衰竭）和肺部疾病（如哮喘或慢性阻塞性肺疾病）的方法。
• Ethanolamine compounds
  申请人：GLAXO GROUP LIMITED

  公开号：EP0162576A1

  公开（公告）日：1985-11-27

  The invention provides compounds of the general formula (I) wherein Ar represents a phenyl group optionally substituted by one or two substituents selected from halogen atoms, or C1-3 alkyl or C1-3 alkoxy groups, or by an alkylenedioxy group of formula -O(CH2)pO- where p is 1 or 2; R, and R2 each represents a hydrogen atom or C1-3 alkyl group with the proviso that the sum total of carbon atoms in R, and R2 is not more than 4; m is an integer from 2 to 8 and n is an integer from 1 to 7 with the proviso that the sum total of m + n is 4 to 12; Q represents a group of formula where R3 represents a hydrogen atom or a C1-3 alkyl group, Ra represents: and Rb represents: where F4 represents a straight or branched C2-3 alkylene chain: and physiologically acceptable salts and solvates thereof. The compounds of formula (l) have a selective stimulant action at (β2-adrenoreceptors and are useful, in particular in the treatment of diseases associated with reversible airways obstruction such as asthma and chronic bronchitis.

  本发明提供通式 (I) 的化合物 其中 Ar 代表苯基，可任选被一个或两个选自卤素原子、或 C1-3 烷基或 C1-3 烷氧基、或式 -O(CH2)pO- 的亚烷基二氧基（其中 p 为 1 或 2）的取代基取代； R 和 R2 各自代表氢原子或 C1-3 烷基，但 R 和 R2 中的碳原子总数不超过 4； m 是 2 至 8 的整数，且 n 为 1 至 7 的整数，但 m+n 的总和为 4 至 12； Q 代表一个式组 其中 R3 代表氢原子或 C1-3 烷基，Ra 代表 和 Rb 代表 其中 F4 代表直链或支链 C2-3 烯链：及其生理上可接受的盐类和溶剂。 式（l）化合物对（β2-肾上腺素受体）具有选择性刺激作用，特别适用于治疗与可逆性气道阻塞有关的疾病，如哮喘和慢性支气管炎。
• Methods of regulating cannabinoid receptor activity-related disorders and diseases
  申请人：The United States of America, as represented by the Secretary, Department of Health and Human Services

  公开号：US10772849B2

  公开（公告）日：2020-09-15

  This disclosure concerns the discovery of the use of fenoterol analogues for regulating cannabinoid (CB) receptor activity-related disorders and disease, such as dysregulated CB receptors, including treating a disorder or disease, such as a glioblastoma, hepatocellular carcinoma, liver cancer, colon cancer, and/or lung cancer, which is associated with altered cannabinoid receptor activity. In one example, the method includes administering to a subject having or at risk of developing a disorder or disease regulated by CB receptor activity an effective amount of a fenoterol analogue to reduce one or more symptoms associated with the disorder or disease regulated by CB receptor activity.

  本公开涉及发现非诺特罗类似物用于调节大麻素（CB）受体活性相关失调和疾病，如失调的CB受体，包括治疗与大麻素受体活性改变相关的失调或疾病，如胶质母细胞瘤、肝细胞癌、肝癌、结肠癌和/或肺癌。在一个例子中，该方法包括向患有或有可能患有受大麻素受体活性调节的紊乱或疾病的受试者施用有效量的非诺特罗类似物，以减轻与受大麻素受体活性调节的紊乱或疾病相关的一种或多种症状。
• Use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas
  申请人：The USA, as represented by the Secretary, Department of Health and Human Services

  公开号：US10925840B2

  公开（公告）日：2021-02-23

  This disclosure concerns the discovery of the use of fenoterol and (R,R)- and (R,S)-fenoterol analogues for the treatment of a tumor expressing a β2-adrenergic receptor, such as a primary brain tumor, including a glioblastoma or astrocytoma expressing a β2-adrenergic receptor. In one example, the method includes administering to a subject a therapeutically effective amount of fenoterol, a specific fenoterol analogue or a combination thereof to reduce one or more symptoms associated with the tumor, thereby treating the tumor in the subject.

  本公开涉及发现非诺特罗及(R,R)-和(R,S)-非诺特罗类似物用于治疗表达β2-肾上腺素能受体的肿瘤，如原发性脑肿瘤，包括表达β2-肾上腺素能受体的胶质母细胞瘤或星形细胞瘤。在一个例子中，该方法包括向受试者施用治疗有效量的非诺特罗、特异性非诺特罗类似物或其组合，以减轻与肿瘤相关的一种或多种症状，从而治疗受试者的肿瘤。
• Synthesis and preliminary evaluation of (R,R)(S,S) 5-(2-(2-[4-(2-[18F]fluoroethoxy)phenyl]-1-methylethylamino)-1-hydroxyethyl)-benzene-1,3-diol ([18F]FEFE) for the in vivo visualisation and quantification of the β2-adrenergic receptor status in lung
  作者：Esther Schirrmacher、Ralf Schirrmacher、Oliver Thews、Wolfgang Dillenburg、Andreas Helisch、Ignatz Wessler、Roland Buhl、Sabine Höhnemann、Hans-Georg Buchholz、Peter Bartenstein、Hans-Jürgen Machulla、Frank Rösch

  DOI：10.1016/s0960-894x(03)00538-9

  日期：2003.8

  The F-18-labeled beta2-adrenergic receptor ligand (R,R)(S,S) 5-(2-(2-[4-(2-[F-18]fluoroethoxy)phenyl]-1-methylethylamino)-1-hydroxyethyl) -benzene-1,3-diol, a derivative of the original highly selective racemic fenoterol, was synthesized in an overall radiochemical yield of 20% after 65 min with a radiochemical purity higher than 98%. The specific activity was in the range of 50-60 GBq/mumol. In vitro testing of the non-radioactive fluorinated fenoterol derivative with isolated guinea pig trachea was conducted to obtain an IC50 value of 66 nM. Preliminary ex vivo organ distribution and in vivo experiments with positron emission tomography (PET) on guinea pigs were performed to study the biodistribution as well as the displacement of the radiotracer to prove specific binding to the beta2-receptor. (C) 2003 Elsevier Ltd. All rights reserved.